secwatch.observer — SEC 8-K summary
======================================

Issuer:     LifeStance Health Group, Inc. (LFST)
CIK:        0001845257
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0000950170-22-003370
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LifeStance Q4 revenue $190.1M (+61% YoY); net loss $108M; 2022 guidance reaffirmed
--------------------------------------------------------------------------------

- Full-year 2021 revenue $667.5M (+77% YoY); net loss $307.2M largely from stock-based compensation.
- Q4 Adjusted EBITDA $11.4M (6.0% of revenue), down 31% YoY; full-year Adjusted EBITDA $49.2M (7.4% of revenue).
- Clinician base grew 55% to 4,790; 415 net adds in Q4 and 1,693 for the full year.
- 2022 guidance: revenue $865-885M, Center Margin $240-255M, Adjusted EBITDA $63-67M.
- Q1 2022 revenue expected $195-200M; Omicron impact estimated at $3-7M; de novo openings moderated to 80-90.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845257/000095017022003370/0000950170-22-003370-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845257/000095017022003370/lfst-20220310.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-003370

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer